SCHEMBL4416285

SCHEMBL4416285

NC(=O)N1C(=O)[CH]N=C(c2ccc(Cl)cc2)c2ccccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.40
SRC P12931 1/20 0.40
FGFR2 P21802 1/20 0.40
FGFR4 P22455 1/20 0.40
FGFR3 P22607 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP3A4 P08684 1/20 0.40
MAPT P10636 1/20 0.40
PABPC1 P11940 1/20 0.40
BLM P54132 1/20 0.40
KMT2A Q03164 1/20 0.40
CCKBR P32239 9/20 0.39
CCKAR P32238 3/20 0.39
BRD4 O60885 3/20 0.37
NOTCH1 P46531 1/20 0.35
RBPJ Q06330 1/20 0.35
PTGS1 P23219 1/20 0.35
PTGS2 P35354 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3180266 0.89 KDM4E (0.43) KDM4EMEN1ALDH1A1CYP3A4MAPT
SCHEMBL3186755 0.85 OPRK1 (0.40) MEN1ALDH1A1KMT2ACCKBRCCKAR
SCHEMBL641926 0.85 OPRK1 (0.47) MEN1ALDH1A1MAPTKMT2ABRD4
SCHEMBL4703950 0.79 OPRK1 (0.48) KDM4EMEN1ALDH1A1MAPTKMT2A
SCHEMBL3183404 0.75 KDM4E (0.37) KDM4EALDH1A1CCKBRBRD4BRD2
SCHEMBL6531565 0.73 HPGDS (0.41) KDM4EALDH1A1
SCHEMBL7066613 0.68 FGFR1 (0.39) FGFR1SRCFGFR2FGFR4FGFR3
SCHEMBL11622848 0.67 MEN1 (0.56) KDM4EMEN1ALDH1A1CYP3A4MAPT
SCHEMBL3968919 0.67 GABRA1 (0.62) KDM4EMEN1ALDH1A1CYP3A4MAPT
SCHEMBL5802442 0.67 KDM4E (0.43) KDM4EMEN1ALDH1A1CYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090318427-A1 BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION ARROW THERAPEUTICS LIMITED (GB) 2009-12-24 US claimed
US-20090318427-A1 BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION ARROW THERAPEUTICS LIMITED (GB) 2009-12-24 US disclosed
EP-1928465-A1 BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION Arrow Therapeutics Limited (GB) 2008-06-11 EP disclosed
WO-2007034127-A1 BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION ARROW THERAPEUTICS LIMITED (GB) 2007-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318427-A1 BENZODIAZEPINE DERIVATIVES FOR TREATING HEPATITIS C INFECTION CNR1, GABRA6, SIGMAR1 FGFR1 4436/4885SRC 3254/4885FGFR2 4532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.